Abstract
Deposition of β-amyloid (Aβ) plaques in the brain is likely linked to the pathogenesis of Alzheimer’s disease (AD). Developing specific Aβ aggregate-binding ligands as in vivo imaging agents may be useful for diagnosis and monitoring the progression of AD. We have prepared a thioflavin derivative, 6-iodo-2-(4’-dimethylamino-)phenyl-imidazo[1,2-a]pyridine, IMPY, which is readily radiolabeled with 125I/123I for binding or single-photon emission computerized tomography (SPECT) imaging studies. Characterization of [125I]IMPY binding to plaque-like structures was evaluated in double transgenic PSAPP mice. [125I]IMPY labeled Aβ plaques in transgenic mouse brain sections, and the labeling was consistent with fluorescent staining and Aβ-specific antibody labeling. Significant amounts of Aβ plaques present in the cortical, hippocampal, and entorhinal regions of the transgenic mouse brain were clearly detected with [125I]IMPY via ex vivo autoradiography. In contrast, [125I]IMPY showed little labeling in the age-matched control mouse brain. Tissue homogenate binding further corroborated the Aβ plaque-specific distribution in various brain regions of transgenic mouse, and correlated well with the known density of Aβ deposition. Using a tissue dissection technique, [125I]IMPY showed a moderate increase in the cortical region of transgenic mice as compared to the age-matched controls. In vitro blocking of [125I]IMPY by “carrier” observed via autoradiography in mouse brain sections was not replicated by an in vivo blocking experiment in living TT mouse brain. The failure was most likely due to a significant carrier effect, which slows down the tracer in vivo metabolism, leading to an increased brain uptake. Taken together, these data indicate that [123I]IMPY is a potentially useful SPECT imaging agent for in vivo labeling of Aβ plaques in the living brain.
Similar content being viewed by others
References
Ginsberg SD, Schmidt ML, Crino PB, Eberwine JH, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer’s disease and related disorders. In: Peters A, Morrison JH, eds. Cerebral cortex: neurodegenerative and age-related changes in structure and function of cerebral cortex. New York: Kluwer Academic/Plenum; 1999:603–654.
Selkoe DJ. The origins of Alzheimer disease: A is for amyloid. JAMA 2000; 283:1615–1617.
Selkoe DJ. Imaging Alzheimer’s amyloid. Nature Biotech 2000; 18:823–824.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297:353–356.
Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE. Synthesis and evaluation of11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46:2740–2754.
Klunk W, Mathis C, Wang Y, Huang G, Holt D, Debnath M, Engler H, Nordberg A, Blomqvist G, Bergstrm M, Estrada S, Barletta J, Sandell J, Antoni G, Lngstrm B. Binding of a benzothiazole amyloid-imaging PET tracer to human brain is dominated by specific interaction with the amyloid component in vitro and in vivo. 32nd Annual Meeting of Society for Neuroscience, Orlando, Florida, 2002.
Ono M, Kung M-P, Hou C, Kung HF. Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer’s disease. Nucl Med Biol 2002; 29:633–642.
Wilson A, Nobrega J, Houle S, Westaway D, Verhoeff NP, Zhuang Z, Kung M-P, Ono M, Kung HF. Radiosynthesis and evaluation of potential β-amyloid imaging radiotracer for PET. J Labelled Cpd Radiopharm 2003; 46:S61.
Agdeppa ED, Kepe V, Shoghi-Jadid K, Satyamurthy N, Small GW, Petric A, Vinters HV, Huang SC, Barrio JR. In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer’s disease patient: a case study [abstract]. J Nucl Med 2001; 42:65P.
Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR, Liu J, Flores-Torres S, Cole GM. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease: binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:24–35.
Zhuang Z-P, Kung M-P, Hou C, Skovronsky D, Gur TL, Trojanowski JQ, Lee VM-Y, Kung HF. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001; 44:1905–1914.
Kung HF, Lee C-W, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 2001; 123:12740–12741.
Lee C-W, Kung M-P, Hou C, Kung HF. Dimethylamino-fluorenes: ligands for detecting β-amyloid plaques in the brain. Nucl Med Biol 2003; 30:573–580.
Kung HF. Synthesis and characterization of125I/123I IMPY as an Abeta-plaque imaging agent. J Nucl Med 2002; 43(5 (Supplement)):166P.
Zhuang ZP, Kung MP, Wilson A, Lee CW, Plossl K, Hou C, Holtzman DM, Kung HF. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem 2003; 46:237–243.
Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 1998; 33:883–889.
Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 1997; 94:1550–1555.
Janus C, Chishti MA, Westaway D. Transgenic mouse models of Alzheimer’s disease. Biochem Biophys Acta 2000; 1502:63–75.
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O’Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. 1998; 4:97–100.
Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O’Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002; 173:183–195.
Kung MP, Hou C, Zhuang Z-P, Zhang B, Skovronsky DM, Gur T, Lee VM-Y, Trojanowski JQ, Kung HF. IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Brain Res 2002; 956:202–210.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996; 274:99–102.
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. 1996; 383:710–713.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193:265–275.
McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon S, Wang R, Mann D, Dickson D, Duff K. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 1999; 6:231–244.
Kung M-P, Skovronsky D, Hou C, Zhuang Z-P, Gur T, Zhang B, Trojanowski JQ, Lee VM, Kung HF. Detection of amyloid plaques by radioligands for Aβ40 and Aβ42: potential imaging agents in Alzheimer’s patients. J Mol Neurosci 2003; 20:15–23.
Dickson DW. Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? 1997; 151:7–11.
Acknowledgements
This work was supported by the grants from the Institute for the Study of Aging (M.P.K.), the National Institute of Health (AG021868 to H.F.K.) and in part by AstraZeneca (Wilmington, DE).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kung, MP., Hou, C., Zhuang, ZP. et al. Characterization of IMPY as a potential imaging agent for β-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging 31, 1136–1145 (2004). https://doi.org/10.1007/s00259-004-1487-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1487-z